Morrison Briggs
- SEC CIK
- 0001654430
In the past year, 1 open-market purchase filing worth $268.0K and no sales.
Current role at each company
- ARVN Arvinas, Inc.Directoras of Jun 26, 2026
- CRSP CRISPR Therapeutics AGDirectoras of Jun 9, 2026
- HOWL Werewolf Therapeutics, Inc.Directoras of Jun 13, 2025
- CARM Carisma Therapeutics Inc.Directoras of Jun 27, 2024
- RPTX Repare Therapeutics Inc.Directoras of Jun 20, 2024
Show 1 more company
- SNDX Syndax Pharmaceuticals IncDirectoras of Feb 9, 2024
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- $268.0K
- 1 filing
- Sold
- –
- 0 filings
- Net
- +$268.0K
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Morrison Briggs as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
ARVN Arvinas, Inc.
Director4 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 19, 2022 (view filing) | Jan 14 | 5 days | Morrison BriggsDirector | SSale | −21.0K | $65.55 | −$1.37M | −45.9%24.7K after | 4 lots |
| Apr 18, 2022 (view filing) | Apr 14 | 4 days | Morrison BriggsDirector | SSale | −21.0K | $66.44 | −$1.39M | −51.2%20.0K after | 3 lots |
| Sep 24, 2025 (view filing) | Sep 22 | 2 days | Morrison BriggsDirector | PPurchase | +30.0K | $7.57 | +$227.1K | +65.2%76.0K after | |
| Mar 9, 2026 (view filing) | Mar 6 | 3 days | Morrison BriggsDirector | PPurchase | +20.0K | $13.40 | +$268.0K | +26.3%96.0K after |
SNDX Syndax Pharmaceuticals Inc
Director13 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 21, 2021 (view filing) | Sep 17-20 | 4 days | Morrison BriggsChief Executive Officer | SSale | −70.3K | $20.07 | −$1.41M | −59.3%48.3K after | 2 lots |
| Dec 20, 2021 (view filing) | Dec 17 | 3 days | Morrison BriggsChief Executive Officer | SSale | −35.2K | $20.00 | −$703.1K | −42.1%48.3K after | |
| Apr 5, 2022 (view filing) | Apr 1-4 | 4 days | Morrison BriggsPresident, Head of R&D | SSale | −104.2K | $17.48 | −$1.82M | −85.4%17.8K after | From original4 lots |
| Jul 5, 2022 (view filing) | Jul 1 | 4 days | Morrison BriggsPresident, Head of R&D | SSale | −62.3K | $19.00 | −$1.18M | −77.7%17.8K after | |
| Sep 16, 2022 (view filing) | Sep 14-16 | 2 days | Morrison BriggsPresident, Head of R&D | SSale | −279.4K | $23.64 | −$6.60M | −94.0%17.8K after | 4 lots |
| Sep 21, 2022 (view filing) | Sep 19-20 | 2 days | Morrison BriggsPresident, Head of R&D | SSale | −174.0K | $23.11 | −$4.02M | −90.7%17.8K after | 2 lots |
| Feb 8, 2023 (view filing) | Feb 6 | 2 days | Morrison BriggsPresident, Head of R&D | SSale | −52.9K | $26.83 | −$1.42M | −74.8%17.8K after | |
| Mar 14, 2023 (view filing) | Mar 13 | 1 day | Morrison BriggsPresident, Head of R&D | SSale | −52.9K | $22.53 | −$1.19M | −74.8%17.8K after | |
| Apr 12, 2023 (view filing) | Apr 10 | 2 days | Morrison BriggsDirector | SSale | −52.9K | $19.53 | −$1.03M | −74.8%17.8K after | 10b5-1 |
| May 10, 2023 (view filing) | May 9 | 1 day | Morrison BriggsDirector | SSale | −52.9K | $21.41 | −$1.13M | −74.8%17.8K after | 10b5-1 |